Overview
This study aims to
- Identify biomarkers and signatures to differentiate between high-risk and lung cancer patients.
- Discover blood-based biomarkers that can be used as an adjunct test to imaging diagnosis to improve patient follow-up.
Description
With existing evidence showing the utility of using liquid biopsy for early cancer detection, the investigators hypothesized that cell-free DNA and/or RNA expression changes during disease progression, and biomarker signature can be derived from the changes in expression levels. The investigators aim to discover and validate RNA and methylated cell-free DNA cancer biomarkers that can discriminate between high-risk and lung cancer patients.
Eligibility
Inclusion Criteria:
- Male or female subjects aged 30 and above.
- No previous history of any cancers.
- Able to provide X-ray and/or LDCT results.
- Have either COPD or pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician
- Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care.
- Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit).
Exclusion Criteria:
- Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.
- Subject is pregnant or lactating (self-declaration).
- Subject is unwilling or unable to provide signed informed consent